Title: The Pharmacology of Antipsychotics -- Similarities and Differences

**Abstract**

The concept that blockade of limbic and dorsal striatal dopamine (DA) D~2~ receptors is the exclusive basis for the efficacy of all antipsychotic drugs (APDs) to treat positive symptoms is still confidently stated as an unquestionable principle of treating schizophrenia. However, its limitations have been evident ever since the evidence for the contribution of serotonin (5-HT)~2A~ receptor blockade as a key target of atypical APDs when associated with weaker D~2~ receptor blockade was discovered nearly 20 years ago, followed by the demonstration that selective 5-HT~2A~ inverse agonists, e.g. M100907 and SR43459B, are effective standalone APDs. These findings contributed to the development of pimavanserin, another selective 5-HT~2A~ inverse agonist) which is expected to be approve for treating L-DOPA psychosis in 2016. Evidence will be presented that pimavanserin can be effective in the treatment of schizophrenia as an augmentation agent for subeffective doses of the atypical APD, risperidone. This general mechanism which can be used to achieve antipsychotic action with minimal weight gain, prolactin elevations and EPS for other atypical APDs. There is also evidence that other 5-HT receptors are targets for APDs, including 5-HT~2C~ agonism, 5-HT~7~ antagonism, and 5-HT~1A~ receptor partial agonism.

Several atypical APDs with potent 5-HT~2A~ receptor inverse agonism, including clozapine, olanzapine, risperidone, and lurasidone, are effective to treat positive symptoms in treatment resistant schizophrenia, especially when administered for more than six weeks. It will be shown that a two week trial is not adequate for non-treatment resistant schizophrenia. Atypical APDs are also more effective to treat the cognitive impairment associated with schizophrenia (CIAS) and cause less Parkinsonism and tardive dyskinesia (TD). There is now evidence that TD is associated with worse cognitive impairment and can diminish the ability of atypical APDs to improve CIAS, possibly via restoring grey matter in cortical brain regions. THE atypical APDs enhance the release of growth factors such as BDNF and restore synaptic structure and function in rodent and primate brain. Direct and indirect actions of atypical APDs at DA D~1~, 5-HT~1A~, 5-HT~7~, nicotinic and muscarinic receptors have been shown in animal models to contribute to restoring cognitive function in various rodent models of CIAS while excessive D~2~ receptor blockade has a negative influence on cognition.

Data from recent GWAS studies will be presented which demonstrate that the efficacy of atypical APDs to improve psychopathology in schizophrenia is mediated by gene products that affect synaptic structure and function, e.g. neurexin and other synaptic adhesion gene products.

The synaptic mechanisms that are required for normal reality testing, rewarded behavior, and higher cognitive function may be impaired by too much or too little stimulation of all five DA receptors, certainly not just D~2~ receptors. The atypical APDs are better able to achieve optimal stimulation of these receptors through a variety of mechanisms, many of which are serotonergic. D2 receptor blockade is not necessary but sometimes sufficient which has led to long standing overvaluation of its importance. The heterogeneity in response to APDs may be related to genetic variations which govern the various ways in which synapses can be made to work effectively.
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